Company Overview and News

0
H2O Innovation Secures Four New Industrial Projects Totalling $3.1 M

2018-06-28 globenewswire
QUEBEC CITY, June 28, 2018 (GLOBE NEWSWIRE) -- H2O Innovation Inc. (TSX VENTURE:HEO) (“H2O Innovation” or the “Corporation”) is proud to announce it was awarded four (4) new industrial projects in North America. These new contracts, worth $3.1 M, will bring the Corporation’s project sales backlog to $55.1 M.
HEOFF ALHEO HEO

0
H2O Innovation remporte quatre nouveaux projets industriels totalisant 3,1 M $

2018-06-28 globenewswire
QUÉBEC, 28 juin 2018 (GLOBE NEWSWIRE) -- H2O Innovation inc. (TSX CROISSANCE:HEO) (« H2O Innovation » ou la « Société ») est fière d’annoncer qu’elle a remporté quatre (4) nouveaux projets industriels en Amérique du Nord. Ces nouveaux contrats, d’une valeur totale de 3,1 M $ porteront le carnet de commandes de projets de la Société à 55,1 M $.
HEOFF ALHEO HEO

0
H2O Innovation Secures Four New Industrial Projects Totalling $3.1 M

2018-06-28 globenewswire
Quebec City, June 28, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") is proud to announce it was awarded four (4) new industrial projects in North America. These new contracts, worth $3.1 M, will bring the Corporation's project sales backlog to $55.1 M.
HEOFF ALHEO HEO

0
H2O Innovation remporte quatre nouveaux projets industriels totalisant 3,1 M $

2018-06-28 globenewswire
Québec, le 28 juin 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière d'annoncer qu'elle a remporté quatre (4) nouveaux projets industriels en Amérique du Nord. Ces nouveaux contrats, d'une valeur totale de 3,1 M $ porteront le carnet de commandes de projets de la Société à 55,1 M $.
HEOFF ALHEO HEO

0
H2O Innovation Inc. 2018 Q3 - Results - Earnings Call Slides

2018-05-16 seekingalpha
The following slide deck was published by H2O Innovation Inc. in conjunction with their 2018 Q3 earnings call.
HEOFF ALHEO HEO

0
Les résultats du troisième trimestre de l'exercice financier 2018 d'H2O Innovation - Ventes record et croissance soutenue pour tous les piliers d'affaires

2018-05-15 globenewswire
Québec, le 15 mai 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») fait connaître aujourd'hui ses résultats du troisième trimestre de l'exercice financier 2018 terminé le 31 mars 2018. Les revenus du troisième trimestre de l'exercice financier 2018 totalisent 26,7 M $, en hausse de 5,4 M $ ou 25,4 %, comparativement à des revenus de 21,3 M $ pour le trimestre correspondant de l'exercice financier précédent.
HEOFF ALHEO HEO

0
H2O Innovation's 2018 Third Quarter Results - Record sales and sustained growth in all business pillars

2018-05-15 globenewswire
Quebec City, May 15, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") announces its results for the third quarter of fiscal year 2018 ended March 31, 2018. Revenues for the third quarter of fiscal year 2018 totaled $26.7 M, representing a $5.4 M or 25.4% increase, as compared with revenues of $21.3 M for the third quarter of the previous fiscal year. This increase is fueled by the organic growth of our three business pillars.
HEOFF ALHEO HEO

0
H2O Innovation remporte cinq nouveaux projets de traitement d'eau et d'eaux usées totalisant 4,1 M $

2018-05-10 globenewswire
Québec, le 10 mai 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière d'annoncer qu'elle a remporté cinq (5) nouveaux projets de traitement d'eau et d'eaux usées en Amérique du Nord. Ces nouveaux contrats, d'une valeur totale de 4,1 M $ porteront le carnet de commandes de projets de la Société à 56,6 M $.
HEOFF ALHEO HEO

0
H2O Innovation Secures Five New Water and Wastewater Projects Totalling $4.1 M

2018-05-10 globenewswire
Quebec City, May 10, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") is proud to announce it was awarded five (5) new water and wastewater projects in North America. These new contracts, worth $4.1 M, will bring the Corporation's project sales backlog to $56.6 M.
HEOFF ALHEO HEO

0
H2O Innovation announces the release of its financial results for the third quarter of 2018

2018-05-01 globenewswire
Quebec City, May 1st, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") announces that it will release its financial results for the 2018 third quarter on Tuesday, May 15, 2018, at approximately 2:00 p.m. Paris Time (8:00 a.m. EDT). The Corporation will also host a conference call, on that same day, at 4:00 p.m. Paris Time (10:00 a.m. EDT).
HEOFF ALHEO HEO

0
H2O Innovation annonce la publication de ses résultats financiers du troisième trimestre 2018

2018-05-01 globenewswire
Québec, le 1er mai 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») annonce aujourd'hui qu'elle publiera ses résultats financiers du troisième trimestre 2018 vers 14h00, heure de Paris (8h00 HAE), le mardi 15 mai 2018. La Société tiendra également une conférence téléphonique, ce même jour, à 16h00 heure de Paris (10h00 HAE).
HEOFF ALHEO HEO

0
H2O Innovation : la ligne d'affaires d'équipement acéricole augmente ses revenus de 20%

2018-04-26 globenewswire
Québec, le 26 avril 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») désire faire une mise à jour sur les activités de sa ligne d'affaires d'équipement acéricole (« H2O Érablière ») qui connait une croissance fulgurante de ses ventes. Sur une période de douze mois, ses ventes ont progressé de 20%, poussées par l'ajout de produits innovants et l'agrandissement de son réseau de distribution nord-américain.
HEOFF ALHEO HEO

0
H2O Innovation: Maple Equipment Business Line Increases its Revenues by 20%

2018-04-26 globenewswire
Quebec City, April 26, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") wishes to make an update on the activities of its maple equipment business line ("H2O Maple"), which is experiencing a massive growth in sales. Over the last twelve months, its sales increased by 20%, driven by the addition of innovative products and the expansion of its North American distribution network.
HEOFF ALHEO HEO

0
H2O Innovation : Piedmont étend son réseau international de distribution et remporte d’importants contrats

2018-04-19 globenewswire
QUÉBEC, 19 avr. 2018 (GLOBE NEWSWIRE) -- (TSX CROISSANCE:HEO) – H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière d’annoncer que sa filiale indépendante Piedmont, leader mondial dans l’équipement anticorrosif pour les usines de dessalement pour les marchés industriels et municipaux, a récemment signé de nouvelles ententes de distribution et remporté de nouveaux contrats pour ses lignes de produits de raccords flexibles et de filtres à cartouches faits de FRP.
HEOFF ALHEO HEO

0
H2O Innovation: Piedmont expands its global distribution network and wins major contracts

2018-04-19 globenewswire
QUEBEC CITY, April 19, 2018 (GLOBE NEWSWIRE) -- (TSXV:HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is proud to announce that its independent subsidiary Piedmont, a global leader in corrosion resistant equipment for desalination plants in the industrial and municipal markets, recently signed new distribution agreements and won new contracts for its coupling and FRP cartridge filter housing product lines.
HEOFF ALHEO HEO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

16h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

17h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...